01—Abstract
Summary
Summary of the 10-Q filed October 23, 2026. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics Inc. (DGX) reported a solid third quarter for 2026, demonstrating robust revenue growth and improved profitability.
Net revenues increased by 10.0% year-over-year to $3,097 milliona, primarily driven by strong performance in the Diagnostic Information Services (DIS) segment, which saw a 10.2% increase. This growth was fueled by a significant 14.5% increase in DIS volume, largely attributed to new partnerships with Corewell Health and expanded services for Fresenius Medical Care. Despite a slight decrease in revenue per requisition due to business mix, overall volume expansion indicates strong demand for Quest Diagnostics' services.
Operating income saw a substantial 24.2% increase to $479 millionb, translating to a 28.7% rise in diluted earnings per share to $2.78. This improvement in profitability reflects effective cost management, including benefits from the 'Invigorate' program aimed at driving cost savings and productivity.
The company also reported healthy operating cash flow of $611 millionc for the quarter. Quest Diagnostics continues to focus on strategic initiatives, including efficiency improvements and growth through partnerships, positioning it well for future performance.
02—Key points
Key Highlights
- Net revenues increased by 10.0% year-over-year to $3,097 million in Q3 2026.
- Diagnostic Information Services (DIS) segment revenue grew by 10.2%, driven by a 14.5% increase in volume.
- Operating income rose significantly by 24.2% to $479 million.
- Diluted earnings per share (EPS) increased by 28.7% to $2.78.
- Net cash provided by operating activities for the quarter was $611 million.
- The 'Invigorate' program continues to contribute to cost savings and productivity improvements.
- New partnerships with Corewell Health and expanded services for Fresenius Medical Care significantly contributed to volume growth.
03—Questions
Frequently Asked Questions
What was the primary driver of revenue growth in the third quarter of 2026?
The primary driver of revenue growth was the strong performance in the Diagnostic Information Services (DIS) segment, which experienced a 10.2% increase in revenue. This was largely due to a significant 14.5% increase in DIS volume, fueled by new partnerships with Corewell Health and expanded services for Fresenius Medical Care, alongside organic growth.
How did Quest Diagnostics manage its costs in the third quarter?
Quest Diagnostics continued to benefit from its 'Invigorate' program, which focuses on driving cost savings and productivity improvements across its operations. While cost of services increased due to higher compensation and supply expenses related to increased volumes, the overall operating income saw a substantial increase, indicating effective cost management and operational efficiencies.
What is the company's outlook based on this quarter's results?
The strong revenue growth, improved profitability, and healthy operating cash flow in Q3 2026 suggest a positive outlook. The company's strategic focus on partnerships, operational efficiency through programs like 'Invigorate', and continued demand for its diagnostic services position it well for sustained performance. The company is also actively managing its capital structure, including debt repayment and share repurchases.
Are there any significant new partnerships or collaborations mentioned in the filing?
Yes, the filing highlights the ongoing impact of a new partnership with Corewell Health to provide Collaborative Lab Solutions and the expansion of laboratory testing services at dialysis clinics owned by Fresenius Medical Care in the United States. These relationships are significantly contributing to the company's volume growth.
04—Continue